News
FDA Approves Wegovy to Treat Serious Liver Disease
The approval makes Wegovy the only GLP-1 therapy cleared to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis. About 14.9 million U.S. adults — or roughly 6% of the population — have the condition, according to the FDA.
Novo's Wegovy picks up 3rd indication with key FDA approval in the liver disease MASH
With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug approved in a severe form of fatty liver disease. | The FDA has signed off on an accelerated approval for Novo Nordisk's Wegovy to treat certain adults with metabolic-associated steatohepatitis.
While the 10-fold increase in dose over injectable Wegovy has raised questions about the launch, Novo Nordisk has assured ...
Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...
Zacks Investment Research on MSN3d
NVO Stock Up on FDA Nod for Wegovy in MASH: More Upside Ahead?
Novo Nordisk NVO announced that the FDA has granted accelerated approval to its blockbuster GLP-1 drug, Wegovy (semaglutide 2 ...
GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.
In a significant development for weight management, the Food and Drug Administration (FDA) announced Wednesday its approval ...
Zacks.com on MSN2d
NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain
NVO rose about 4% on Aug. 18, 2025, after Wegovy won FDA approval as the first GLP-1 therapy for MASH, expanding its reach ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback